Genmab A/S (NASDAQ:GMAB) Shares Sold by Capital International Investors

Capital International Investors lowered its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 41.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,570,909 shares of the company's stock after selling 1,850,708 shares during the period. Capital International Investors owned approximately 0.39% of Genmab A/S worth $53,398,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after acquiring an additional 139,722 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new position in Genmab A/S in the 4th quarter valued at approximately $33,804,000. Marshall Wace LLP grew its stake in shares of Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after acquiring an additional 694,243 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Genmab A/S by 18,959.1% during the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Genmab A/S by 3,049.3% in the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after purchasing an additional 394,670 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Up 0.2 %

NASDAQ:GMAB traded up $0.05 during trading hours on Friday, reaching $20.59. 715,569 shares of the company's stock were exchanged, compared to its average volume of 1,046,717. The company has a 50-day moving average of $20.50 and a 200 day moving average of $21.08. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The firm has a market capitalization of $13.63 billion, a price-to-earnings ratio of 11.83, a P/E/G ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GMAB shares. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.